23 ms·
FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower
- russdill 8y agoThis hopefully surprises no-one. Teva and Mylan are very similar companies with very similar profit strategies: https://www.fool.com/investing/2017/10/11/mylan-deals-a-blow-to-teva-pharmaceutical.aspx https://www.fool.com/investing/2017/10/11/mylan-deals-a-blow...
- russdill 8y agoThis also comes as Teva, Mylan (and others) are facing a price fixing lawsuit: https://www.beckershospitalreview.com/pharmacy/20-generic-drugmakers-must-answer-price-fixing-lawsuit.html https://www.beckershospitalreview.com/pharmacy/20-generic-dr... And also a criminal probe (not sure what the status of these are): https://www.bloomberg.com/news/articles/2018-04-24/generic-drug-companies-said-to-face-first-charges-in-u-s-probe https://www.bloomberg.com/news/articles/2018-04-24/generic-d...
- pravda 8y agoWhy would the price be any lower? If it costs $12.53 to manufacture an EpiPen equivalent, and the market price of the EpiPen is $300, it would make no sense to sell it for any price other then $300.
- deleted 8y ago[deleted]
- jimmy1 8y ago/r/LateStageCapitalism/ But if you are being serious... Because $300 dollars for a drug that people rely on to live is too high, and it makes more economical sense to continue to sell alive people a drug at a price they can afford for longer, than keep selling it at $300 for a short time, until they go bankrupt and die.
- mythrowaway1124 8y agoYou're assuming your conclusion. Why should the market price be $300? If it only costs $12.53 to manufacture, someone could sell epipen equivalents for much less than $300 and capture the whole market.
- skksjsnaahs 8y agoSuppose there are only two competitors and the barrier to entry for a third is high. You profit $287.47 per unit with partial market share. If you try to charge $200 so you only make $187.47 per unit, your competitor will also lower the price to $200 and you will both end up with the same market share but less profit. Even if the two participants in the market never communicate, the obvious strategy in a two-player game is keep the high price.
- deleted 8y ago[deleted]
- antisthenes 8y ago> Even if the two participants in the market never communicate, the obvious strategy in a two-player game is keep the high price. No, it isn't. The default strategy is not collusion. It's lowering the price to capture more of the market.
- philipov 8y agoOne should be hesitant to proclaim knowledge of the optimal strategy without knowing all the details. Whether or not the default strategy is to cooperate or betray is sensitive to the precise weights of the rewards for each combination of decisions, as well as the number of times the game is played. For example, in the simple version of the Iterated Prisoner's Dilemma, the optimal strategy is tit-for-tat: the default is to cooperate, and only betray in exchange for being betrayed.
- TeMPOraL 8y agoThat's only default for actors that are dumb. Most humans are smart enough to take advantage of an obviously better strategy that also doesn't really require coordination.
- mtgx 8y agoCan you really say the "market price is X" when there's only been one company making it? Either way, I think there are some hidden forces here that keep these prices so high. Like if the FDA would open the market to competitors from Europe, or even countries like India, I think that "market price" you say would dramatically lower. I think the U.S. pharmaceuticals market both lacks competition from generics, as well as has some weird laws like "Medicare can't negotiate prices with pharma companies," which only encourages pharma companies to raise their prices as much as possible. The law I mention is almost solely responsible for all the "drug X increased price by 5,000%" headlines you've seen lately. Pharma companies have figured out they can shamelessly rob taxpayers and nobody will do a thing about it, as long as they donate to the right politicians (from both parties).
- thaumasiotes 8y agoMedicare has a different negotiation system built in -- Medicare reimburses a fixed percentage of the minimum amount you charge, to anyone under any circumstances, for the same procedure. This means that doctors who accept Medicare have a price floor set for everyone else by the minimum they need to get from Medicare patients. (Yes, procedures from doctors aren't the same thing as drugs from manufacturers.)
- refurb 8y ago"Medicare can't negotiate prices with pharma companies" That's a common statement, but not really true. Medicare Part D, which covered prescription drugs, is managed by private insurers who can negotiate for the price of drugs. In Medicare Part B, which covered physician administered drugs, Medicare pays the average sales price. Which means every time a private insurer gets a lower price, some of that is passed onto Medicare. So the statement "Medicare can't negotiate drug prices" is technically true, but ignores all the other ways it can get lower drug prices.
- niftich 8y agoIt's worth noting that the Teva device that's the subject of the article is what the FDA considers an 'Authorized Generic'. From the press release [1]: >"An authorized generic is made under the brand name’s existing new drug application using the same formulation, process and manufacturing facilities that are used by the brand name manufacturer. The labeling or packaging is, however, changed to remove the brand name or other trade dress. In some cases, a company may choose to sell an authorized generic at a lower cost than the brand-name drug product." While this is different from what common language calls a 'generic drug' [2], in some cases either kind of "generic" could, may, or must be substituted by pharmacists, depending on various circumstances and the particular state's regulatory regime [3]. This interacts with the epinephrine autoinjector market in two ways. First, there is little upside for the manufacturer of the authorized generic to make the list price significantly lower, as the list price is rarely paid by the end-user out of pocket, and frequent mandatory substitution laws cause makers of Authorized Generics to gain marketshare as long as they're slightly cheaper than the brand Second, Authorized Generics of combination devices are only subsitutable for a corresponding brand, so different devices like Auvi-Q and Adrenaclick are technically a different market entirely: the doctor's prescription will note the exact sort of device. Therefore, while there are other epinephrine autoinjectors, the marketshare among them is decided in doctor's offices and insurance plans, rather than by direct consumer choice through the end-user's own spending. [1] https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm617173.htm https://www.fda.gov/newsevents/newsroom/pressannouncements/u... [2] https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm126389.htm https://www.fda.gov/drugs/developmentapprovalprocess/howdrug... [3] (2008) (for illustration only) https://www.uspharmacist.com/article/generic-substitution-laws https://www.uspharmacist.com/article/generic-substitution-la...
- cgag 8y agoWhy would I buy a knockoff for the same price?
- exabrial 8y agoI previously worked for a prescription claim processor and can answer this. The unique thing about the Drug market is there are no knockoffs. A "Brand Name" drug in the USA has the _exact_ same active ingredients (and sometimes inactive, take inhalers) as the Generic. Even more hilariously, most drug companies will create a "generic" version of their drug as well as a "branded" because they can sell the same exact thing at a higher price point.
- antiterra 8y agoThat’s not entirely true when talking about auto-injectors that may or may not have needle hiding mechanisms, convenient form-factor, simple or well-known operation, or voice narration (auvi-q). I am a parent of two young children with tree nut allergies, and I strongly prefer the Auvi-Q despite them gouging my insurer/employer. I use the generic epi-pen for school and child care since that’s what teachers are familiar with. List price for Auvi-Q is around $5000 an injector. I carry _four_ of them everywhere I go. It’s utterly ridiculous for a dose of medicine worth less than $2, but when I need to use one I’m glad I’m not using a syringe or more complicated off-brand.
- exabrial 8y agoI was specifically referring to drugs, medical devices are a completely different animal.
- antiterra 8y agoAre you misunderstanding that the ‘medical devices’ I was referring to are just like the Epi-Pen, and pre-filled with epinephrine for one-time use? I assume your reference to inhalers was to drugs similar to albuterol that include aerosol delivery ‘devices.’
- deleted 8y ago[deleted]
- aaavl2821 8y agoTypically each new entrant prices lower than the previous entrant to gain market share. The PBMs and retailers already buy the Mylan authorized generic, which is the same product and same price as the Teva product. So they have ability to tell Teva that they need to drop the price or they wont work w them. This is a typical dynamic in newly generic pharma markets
- russdill 8y agoThe "easy" way to fix this is to take the market out of the equation.
- warent 8y agoDo you suppose it could be feasible to create a nonprofit organization which produced low price EpiPens that made just enough to cover expenses?
- nathancahill 8y agoFour Thieves Vinegar Collective: https://motherboard.vice.com/en_us/article/43pngb/how-to-make-your-own-medicine-four-thieves-vinegar-collective https://motherboard.vice.com/en_us/article/43pngb/how-to-mak... Discussion on HN: https://news.ycombinator.com/item?id=17629436 https://news.ycombinator.com/item?id=17629436
- sigstoat 8y agopart of what you're paying for with your drugs is quality control to ensure that you 1) made what you wanted to make 2) didn't contaminate it with something you didn't want.
- morpheuskafka 8y agoYou should take a look at the documents I FOIAd from FDA (the parts they didn't redact that is--apparently my appeal will take 3 years to be processed). Median Medical Technologies, Inc. (a Pfizer company that produces and owns patents for the EpiPen) violated numerous safety rules and breached aseptic manufacturing multiple times, and did not appropriately investigate failures. Here's one of their violation letters, I was told that sanctions were still being considered for the latest inspection. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm574981.htm https://www.fda.gov/iceci/enforcementactions/warningletters/... https://drive.google.com/drive/folders/1BgduIfkAL4SaYVQu1yyJXp08q9kJJGa7?usp=sharing https://drive.google.com/drive/folders/1BgduIfkAL4SaYVQu1yyJ...
- sigstoat 8y agoi don't know what else mylan makes, or how much is epipens, or whatever, but if we look at their 2017 financials, and removed all R&D, they'd have had a profit of ~1.2B on total revenue of ~11.9B. so they could shave an average of 10% off the cost of their product line and still break even. maybe there are other places costs can be cut, but as you'd expected ( http://www.aei.org/publication/the-public-thinks-the-average-company-makes-a-36-profit-margin-which-is-about-5x-too-high-part-ii/ http://www.aei.org/publication/the-public-thinks-the-average... ) they're not wildly more profitable than other companies.
- dev_dull 8y agoSo, why not just import these pens from UK or Canadian producers who make them at scale and for much cheaper? Or better yet, create a joint venture to manufacture them cheaply in places like India?
- warent 8y agoUnless I'm misunderstanding, it has nothing to do with production cost in the US, and everything to do with the arbitrarily high market value of the drug.
- russdill 8y agoIt's not the drug, it's the FDA approved one use delivery system. Epinephrine is dirt cheap.
- Symmetry 8y agoThat would be quite illegal, those UK and Canadian epiphendrine injectors haven't been subject to FDA regulation. It would be a really good idea, granted, but there are plenty of less radical ways to solve the problem. It doesn't seem to have a positive effect on health outcomes (due to effects on availability) but US drug regulations are pretty much the tightest in the world and allowing foreign imports would be a relaxation of that.
- amyjess 8y agoUnless the drug in question is a controlled substance, it's only illegal to sell Rx-only medications, not to buy them. On the extremely rare chance customs confiscates your shipment (which in practice only happens one week a year, during Operation Pangea), all that will happen to you is that your package will be empty. I'm not linking them here (just because I don't want to get YC/HN in trouble), but there are a number of highly-reputable online pharmacies in India and Vanuatu that sell non-controlled medications and ship to the US. I haven't checked whether or not they sell EpiPens, but I wouldn't be surprised. I'm aware of them because they are very popular in the transgender community due to high barriers to accessing medical care by legitimate means.
- refurb 8y agoThis article hints at it, but this is the list price that nobody actually pays. Manufacturers offer discounts to pharmacies that lower the net price. So in fact, this drug could be cheaper than the Mylan version, but it looks like they never dug in deeper to find out if it's true. Second of all, the first generic approved gets 180 days of market exclusivity whereby the FDA will not approve any other generic versions. This is such that the generic manufacturer can recoup the investment prior to widespread competition that drives down prices. For example, Lipitor went generic and the price dropped only ~10-20%. After the 180 days, multiple generic companies got approval and now the price is 80-90% lower.
- aeturnum 8y agoUh, sure? The Mylan version will also probably cost less than list for most people (though Mylan will get their money, just like the generic maker). Also, you're correct that the price will come down over time. If the FDA had said, "this approval is part of a process that will eventually lower the cost within the next couple of years," then the article would make no sense. That's not what they said when this generic version was released. The article is not claiming that generic drugs don't reduce prices. It is claiming that the narrative from the FDA, that this approval will reduce costs, is largely false.
- Retric 8y agoThe list prices hold up better without this competition. So, the actual price people pay for either drops even when the genric version has a very similar list price. However, it drops even more in 180 days.
- refurb 8y agoYes, the article states that the Mylan product can be purchased for under $150 with a discount. In fact, several large retailers sell EpiPen for $150 when including a coupon, according to GoodRx. As for the FDA narrative not being true, how do you know that? The article doesn't actually state the true cost of the Teva product anywhere, which was my original point.
- dpeck 8y agoWhat happened to the lower cost generic offering that CVS was touting all over last year? Is it not pushing down prices across the board? https://arstechnica.com/science/2017/01/cvs-just-announced-a-super-cheap-generic-alternative-to-epipen/ https://arstechnica.com/science/2017/01/cvs-just-announced-a...
- gamblor956 8y agoThey have been offering it for more than a year in stores... https://www.cvs.com/content/epipen-alternative https://www.cvs.com/content/epipen-alternative
- Sam_Odio 8y ago> The pricing appears to undercut a notion promoted by FDA officials that approving more generics can help relieve the pocketbook pressure many Americans feel over the cost of their medicines. I'm surprised the author is making the arugment that more competitiion doesn't drive down prices - despite the large body of evidence to the contrary. It's accepted belief that when competition fails to drive down pricing among pharmaceuticals, it's usually due to regulatory decisions. There are several studies that have been done on this exact topic, one even finds that price regulation actually leads to higher prices by discouraging market forces [1]. 1. https://www.regjeringen.no/globalassets/upload/kilde/hod/hdk/2006/0016/ddd/pdfv/291420-vedlegg.pdf https://www.regjeringen.no/globalassets/upload/kilde/hod/hdk...
- Symmetry 8y agoNormally competition means companies can make as many of a product as they want in order to gain market share from each other. FDA regulated drugs often operate on a production quota system where a given company is only allowed to manufacture a pre-approved amount. If the FDA decreased the EpiPen quota by the same amount that the generic was allowed to be produced in then you might not expect to see any reduction in price. Of course they might have just left EpiPen's quota the same, the article doesn't have that sort of information and it might not be publicly available.
- nordsieck 8y ago> FDA regulated drugs often operate on a production quota system where a given company is only allowed to manufacture a pre-approved amount. My understanding is that this only applies to Schedule I and II drugs. The Epipen, along with most other pharmaceutical drugs, do not fall under those categories.
- stallmanite 8y agoAre schedule I drugs allowed to be manufactured at all? I thought schedule I meant the FDA has determined that no medical use exists.
- 8y ago
- Shivetya 8y agoWell the part that matters the most is that the FDA has increased the number of generics approved and as long as that statistic keeps improving without putting anyone at risk it is a good thing.
- misiti3780 8y agoI recently found out I have an allergy but do not know what it is. I tried to buy an EpiPen in NYC and I was told 1. 2 pens cost > $400 usd 2. They have not had any in NYC for over 2 months because of shortages
- haggy 8y agoI read that as "$400 used" and I was about to freak out thinking of what a used EpiPen would be...
- tschwimmer 8y agothe industry prefers the term "certified preowned"
- NullPrefix 8y ago>I certify that this product was owned by somebody else.
- dboreham 8y agoHmm...odd. We previously would buy my son's EpiPens in Canada (when in Canada for other reasons), but recently CVS has had an equivalent product that we've bought. I forget the price but the fact I forget it tells me it was reasonable. ...<digs pen out>...ok, it is made by "Impax" and labeled "epinephrine injection, USP"
- niftich 8y agoThe product you got at CVS [1] is made by Impax and is an FDA 'Authorized Generic' [2] for Adrenaclick, also made my Impax. It's effectively Adrenaclick with the branding intentionally omitted, and the CVS out-of-pocket price is 109.99 USD for pack of two. [1] https://www.cvs.com/content/epipen-alternative https://www.cvs.com/content/epipen-alternative [2] https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm126389.htm https://www.fda.gov/drugs/developmentapprovalprocess/howdrug...
- aaavl2821 8y agoThe price will probably be lower, as the article suggests, but there are currently epipen shortages so teva can charge more until the shortages are resolved. Typically the second generic product brings the largest price reduction [0]. However epipen is a unique scenario. I'm not sure how hard it is to develop a generic epipen, but it is definitely not a straightforward small molecule generic, so presumably there will be fewer generic versions than you see with drugs like lipitor. So it is possible that the market resolves to an oligopoly with 3-5 players that all make decent profits; there is precedent for this (i think the pancreatic enzymes market is an example) [0] https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm129385.htm https://www.fda.gov/aboutfda/centersoffices/officeofmedicalp...
- deleted 8y ago[deleted]
- btilly 8y agoA generic epipen is not only not hard to develop, but you can find youtube videos explaining how to build one yourself. See https://spectrum.ieee.org/the-human-os/biomedical/devices/hackers-offer-a-diy-alternative-to-the-600-epipen https://spectrum.ieee.org/the-human-os/biomedical/devices/ha....
- opencl 8y agoIt's not even 'building' one, it is literally just buying a commercially available FDA approved autoinjector and a vial of epinephrine to load into it. It is really strange that the FDA is totally fine with diabetics buying vials of insulin and loading their own autoinjectors, but doing the same thing with epinephrine is apparently extremely dangerous and the FDA doesn't want you to do it[1]. [1] https://www.in-pharmatechnologist.com/Article/2016/09/22/US-FDA-warns-against-30-alternative-to-Mylan-s-EpiPen https://www.in-pharmatechnologist.com/Article/2016/09/22/US-...
- function_seven 8y agoThis is a devil's advocate argument, but the difference is between one person who routinely uses the drug versus another who may go for years before needing to use it in an emergency situation. The EpiPen is designed to be used with minimal training. A diabetic who injects themselves regularly with insulin is presumed to have the skill to do it without screwing it up.
- dmix 8y agoObligatory: http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-drugs-vs-chairs/ http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-dr... It all goes back to the original problem. Even when the FDA gets their act together and let a single competitor compete it still has a ripple effect.
- scottshea 8y agoMy daughter has used the Auvi-Q as an alternative. In addition to the active injectors they provided a test one that helped her when the time came: https://www.auvi-q.com https://www.auvi-q.com I have not heard of any issues with Auvi-Q since it was reintroduced
- lostcolony 8y agoAuvi-Q's pricing is weird. It's free if you have insurance (whether or not insurance pays for it), and free if your household makes < $100k. If you pay cash for it because neither of those is the case, it's $360. And if insurance pays for it, it's $4500. https://www.forbes.com/sites/matthewherper/2017/01/19/epipen-competitor-auvi-q-to-be-free-for-most-patients-but-cost-4500-for-insurers-in-rube-goldberg-scheme/ https://www.forbes.com/sites/matthewherper/2017/01/19/epipen... That said, I have it too; it was free to me because I have insurance. But this area really needs proper regulation and cost controls.
- anonymous54249 8y agoI asked my son's allergist about those, and was surprised to learn that they cost an order of magnitude more than epi pens. He wouldn't prescribe them because he refuses to support that kind of pricing. BTW epi pens also come with a tester. (We have insurance so we pay a small copay for epi pens and auvi-q would be free.)
- scottshea 8y agoInteresting. Our allergist said almost the exact opposite in that they refused to prescribe EpiPen because it was so much higher than Auvi-Q. And I wonder when EpiPen started issuing testers. We had them for years (me first, then my daughter) and never got one.
- lostcolony 8y agoCost to patient, or cost to insurance. Auvi-Q is much greater cost to insurance, less to patient. The former is still a major concern given how that leads to increased premiums and general medical pricing inflation, even if it briefly benefits the individual.
- creaghpatr 8y agoThe former pharma exec working for HHS to negotiate lower drug prices committed suicide about a month ago. https://www.cleveland.com/metro/index.ssf/2018/11/death_of_hhs_official_daniel_b.html https://www.cleveland.com/metro/index.ssf/2018/11/death_of_h...
- inetknght 8y ago> suicide > multiple blunt force injuries Maybe I'm just a conspiracy theorist but I'm curious to learn more
- lightbyte 8y ago>Police say Best was found "unresponsive" near the garage door exit of an apartment building A non-conspiracy possibility is he used the garage door to commit suicide, and the bouncing door is what caused the blunt force injuries
- ams6110 8y agoUnlikely. Garage doors have safety mechanisms that will reverse or at least stop a closing door if there's an obstruction. My guess was that he jumped from the roof, and was found by the garage door. That would explain the blunt force trauma.
- SlowRobotAhead 8y agoThey also don't have anywhere near the amount of torque required to smash a person.
- gojomo 8y agoA better explanation consistent with "blunt force injuries" is a jump from several floors up.
- deleted 8y ago[deleted]
- 8y ago
- tmaly 8y agoI think the article should state clearly if the price is with or without health insurance. I bought a generic epipen this year for my daughter and the co-pay was $4.
- munk-a 8y agoI agree that this article is misleading but the cost to consume is super hard to get to in most cases. Most pharma companies don't know what price the end consumer ends up paying due to all the complications of the convoluted health insurance system, to find the cost and prior authorizations of a drug you may need to consult a dozen separate documents, and if you've got spousal insurance all that complication doubles or more.
- shmerl 8y agoWhy should adrenaline shot be so crazy expensive? Nothing about it sounds complicated.
- Unibod 8y agoPossibly my first post, so sorry if I have make faux pas. In the UK the national health service [NHS] engages nationally to negotiate price. They have the concept of the value of a medicine compared to the improved quality of life it brings. As a result generic medicines are priced against their value. This means that an epipen is priced at £45 or about $60. Google Lloyds pharmacy epipen - UK only search. I rather like this approach to healthcare, I am not sure about transnational ability to buy this - but to those that need it I hope you can make it work. My observation is that the UK approach to healthcare has some advantages in its approach, it is not without faults but value for money [affordability] is embedded in delivery.
- pessimizer 8y agoThere was not a chance that the price of EpiPen was going to go down. Manchin exists, and Democrats were going to have to drive change. Once Shkreli was jailed for charges completely unrelated to drug pricing, all of the gas was taken out of the media panic. Bresch was an excellent choice for a CEO, even without an MBA. In my experience 99.9% of people I talk to think that Shkreli went to jail for drug overpricing, take some patriotic joy from that fact, and think that one of the results of his jailing is that EpiPens are cheaper. It's like how everybody thought that Saddam did 9/11.
- deleted 8y ago[deleted]
- Animats 8y agoA rule of thumb from the European Union is that it takes four competitors before prices come down. Two form a duopoly, and it's to the advantage of both parties not to lower prices. Four have trouble holding prices up. Whoever's losing market share tends to cut prices. Antitrust law needs to reflect the rule of four.
- Apocryphon 8y agoSo that explains T-Mobile's Un-carrier play.
- simonbyrne 8y agoAny studies you can link to?
- Animats 8y agoSee [1], section "Number of competitors", page 12. This isn't a policy document, but an EU study. An interesting result in that paper is that low interest rates make tacit collusion more profitable. We've been in a period of very low interest rates for some time now, which increases the number of competitors for whom tacit collusion pays. As before, collusion is sustainable if and only if firms put a sufficient weight on future profits. The critical threshold for the discount factor, δ, now depends on the number of firms: the more competitors there are, and the higher this threshold, meaning that collusion is less and less sustainable. For example, the threshold increases from 1/2 = 0.50 to 1/3 = 0.67 when the number of competitors increases from 2 to 3. This means that if the firms’ discount factor lies around 0.60, say, two “competitors” could in fact maintain the monopoly outcome but three or more competitors would have to price at cost. [1] http://ec.europa.eu/competition/mergers/studies_reports/the_economics_of_tacit_collusion_en.pdf http://ec.europa.eu/competition/mergers/studies_reports/the_...
- TheSpiceIsLife 8y agoOr, a government could just say: If you want to operate as a pharmaceutical producer / seller in this country, you have to supply this list of emergency medicines at 10% above the price we can import from China / India.” And be done with it. Edit: fixed a typo
- pkaye 8y agoWhy is there such an increasing demand for EpiPen type products? Are more people becoming allergic to stuff?
- tropdrop 8y agoYes. Food allergy in children has increased 50% from 1999 to 2011 [1]. 1. https://www.foodallergy.org/sites/default/files/2018-04/FARE-Food-Allergy-Facts-Statistics.pdf https://www.foodallergy.org/sites/default/files/2018-04/FARE...
- londons_explore 8y agoThat linked document is really good. Every medical topic should have a factsheet, with lots of citations and links to studies, produced for it like this.
- londons_explore 8y agoWhen the cause of food allergies is discovered, a lot of people are going to laugh at how quite so many people could be affected before we found out which chemical causes them.
- tracker1 8y agoWith the number of changes in farming and GMO products, production soil, other effects of industrial farming, etc, etc, it's not surprising. More diversity in marriage and resulting younger generations can also change/increase allergy profiles as well, since you may now have reactions to things that effect either parent or to a greater extent. It's complicated, to say the least. Also, you can go most of your life with smaller reactions to something before it starts to get bad. (Discovered legume allergy at 40yo)
- deleted 8y ago[deleted]
- timwaagh 8y agoi think it could be much worse. the fact that there is a competitor means the former monopolist cannot raise prices of their 'lets avoid a scandal' $300 version back up to 600, which is closer to the profit maximising price for the product in a monopoly market.
- tracker1 8y agoLimit patent licensing for medical patents for prescribed medications to $15 each, or $1/day which ever is less. Limit patent licensing to $50 for prescribed devices. Reduce extension patents on medications or medical devices to no more than 5 years (same for software). Make it take an act of congress to change/raise those amounts in the future with a super majority.